Telomerase activity has been found in ～85-90％ ofall human tumors but not in adjacent normal cells.This makes telomerase a target not only for cancerdiagnosis but also for the development of novel genetherapeutic agents. Among nucleic acid-based methodsfor controlling gene expression，antisense(AS)therapies are potentially powerful candidates forclinical treatments of various ailments，includingcancer. In conventional AS approaches，antisenseoligodeoxynucleotides(ASODNs)designed to hybridizewith target mRNA sequences down regulate theexpression of the corresponding translated proteins.Although ASODNs have emerged as an exciting andpromising strategy in the field of cancer therapy inrecent years，their development in viable therapeuticsystems has faced challenges due to theirsusceptibility to enzyme degradation and poorintracellular uptake. Therefore，suitable drugdelivery systems are needed to develop foreffectively improving cellular uptake and stabilityof ASODNs.
展开▼
